Effect – The results from the highly anticipated Evoke Phase 3 clinical trials evaluating oral semaglutide as a potential treatment for Alzheimer’s disease have brought a mix of clarity and disappointment to the scientific community.,…
Funding – Clinical trials are the backbone of medical progress. They test new drugs, vaccines, devices, and treatment strategies that eventually become mainstream healthcare solutions.,…
Ivermectin – A Look at the Off-Label Use of Ivermectin During the COVID-19 Pandemic and the Global Debate Around Its Efficacy and Safety The COVID-19 pandemic, which began in late 2019, sparked an urgent global search for effective treatments.
Leqembi Found Safe for Use in Memory Clinics: A Step Forward in Alzheimer’s Treatment Accessibility. Leqembi (lecanemab), a monoclonal antibody developed by Eisai and Biogen, has recently been recognized as safe for use in memory clinics, marking a significant advancement in the treatment of early-stage Alzheimer’s disease
A new experimental drug is showing promise in slowing the progression of disability in individuals with multiple sclerosis (MS), according to recent findings from a large clinical trial. The results have sparked optimism among patients, neurologists, and researchers alike, as current treatment options for MS often focus primarily on managing symptoms rather than significantly altering the course of the disease.
Alzheimer’s disease, a progressive neurodegenerative disorder, affects millions of people worldwide, leading to memory loss, cognitive…
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord.
